Company / Free Cash Flow
Biogen Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$2.1B
FY2025
5-year range
$1.1B / $3.4B
FY2021-FY2025
Trend
-24.7%
vs FY2024
Sector context
#11 of 192
Health Care
What the data says
Among 192 Health Care companies, Biogen is in the top 6% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from $1.1B in FY2022 to $6.6B in FY2019.
Based on SEC 10-K filings.
$2.1B in FY2025 with a 5-year CAGR of -11.6%. Top quartile in the Health Care sector.
Improved from $1.3B to $2.1B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +21.5%
- 5-Year CAGR
- -11.6%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 192This company $2.1B Sector average $474.2M
▼
+332.5% above sector average
Key checks
Key Insights
- 5-year CAGR of -11.6%, indicating a declining trend.
- In FY2025, free cash flow decreased 24.7% year-over-year.
- Ranks #11 out of 192 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1B | -24.7% |
| FY2024 | $2.7B | +114.3% |
| FY2023 | $1.3B | +11.0% |
| FY2022 | $1.1B | -66.2% |
| FY2021 | $3.4B | -11.1% |
| FY2020 | $3.8B | -42.0% |
| FY2019 | $6.6B | +21.2% |
| FY2018 | $5.4B | +47.1% |
| FY2017 | $3.7B | -7.2% |
| FY2016 | $4.0B | +21.2% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026